Hi ,

Save the Date for the SynBioBeta - Molecule Twitter Spaces: Oct 10th 8:00 - 9:00 am PT 

DeSci Deep Dive with CEO of Molecule Paul Kohlhaas and Founder & CEO of SynBioBeta John Cumbers

I'm hosting my good friend Paul Kohlhaas, CEO of Molecule, for a deep dive on Twitter Spaces. Come find out more about DeSci and why I'm so excited about it. You can sign up here.

Insights:

• Ginkgo Bioworks and Novo Nordisk are Shifting the SynBio-Biopharma Narrative. Synthetic biology's potential extends beyond faster drug production to the creation of personalized medicines that could bypass traditional manufacturing.

• The Compact CRISPR Enzyme Promising Breakthroughs in Genetic Medicine. In a groundbreaking development published in Cell, scientists have unveiled a new, compact CRISPR-based gene-editing tool, AsCas12f.

Industry News:

• Nobel Nods: The Penn Pioneers Powering the Pandemic Response. Karikó and Weissman's relentless pursuit of mRNA's potential has earned them the coveted 2023 Nobel Prize in Physiology or Medicine

• Robertet and Interstellar Lab: Sowing the Future of Natural Ingredients. Robertet, a global titan in the realm of natural raw materials, has taken a pioneering leap by becoming the first in the fragrance and flavor industry to embrace the BioPod, a creation of the visionary biotech startup Interstellar Lab.

• Carbon-Capturing Cultures: Marine Microbes in the Fight Against Greenhouse Gases. An innovative enzyme-electrode duo efficiently transforms CO2 into formate, offering a new method for carbon capture and green energy storage.
  

• Reshaping Biomanufacturing with Intelligent Fermentation Technology. Pow.Bio raises $9.5M to deploy the first-ever AI-controlled, continuous automated fermentation platform at scale
  

Other news:

• Pfizer Will Leverage Ginkgo’s Proprietary RNA Technology to advance the discovery and development of novel RNA molecules across priority research areas. (Press Release)

• Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies (Press release)

• UK Gene Editing Startup Pencil Biosciences raises £5.6 million Seed funding to develop its non-CRISPR gene editing platform for rare diseases and cancer treatments. (Tech.eu)

• Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development: New investor OrbiMed expects platform to reduce development time for novel treatments and therapeutic approaches (Press release)

• Join the 2023 Tri-Valley Life Sciences Summit on October 18 in Pleasanton, CA, hosted by Unchained Labs and presented by Tri-Valley Ventures, Mirador Capital Partners, and Metcon with Startup Tri-Valley and California Life Sciences. (Event)

• Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing: Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a more scalable and less expensive process than current methods. (MedCity News)

• What can cell-free protein synthesis do for you? Discover the frontiers of synthetic biology and cell-free protein synthesis in a webinar led by Professor Michael Jewett. (Webinar)

• Introducing Future Society: A Collection of Never-Before-Experienced Perfumes Derived from the DNA of Extinct Flowers.

• Endolith, a Cemvita subsidiary, Secures $1.1M DOE Grant to Accelerate Lithium Program for Commercial Deployment with Industry Partners. (Press release)

• Nosh.bio partners with Ginkgo Bioworks to develop animal-free meat alternatives (Tech.eu)

• ‘We are just getting started’: the plastic-eating bacteria that could change the world (The Guardian)

Regards,

John

---

John Cumbers

CEO, SynBioBeta

Who's hiring?

• Research Associate, Molecular Biology & Strain Improvement at Checkerspot (Alameda, CA)

• Bioprocess Scientist at Peptobiotics (Singapore)